(Source: Oncolytics Biotech.)
  • U.S.-listed shares of BELLUS Health Inc. (NDAQ:BLU) rallied 97.6 per cent in premarket trading on a major offer
  • GSK Plc (NYSE:GSK) plans to buy the Canada-based drug developer in an all-cash deal for $2 billion
  • Both companies announced the deal on Tuesday, which revolves round BELLUS’ experimental drug, camlipixant, which is in late-stage development for refractory chronic cough
  • BELLUS Health Inc. (BLU) opened trading at C$9.71 per share

U.S.-listed shares of BELLUS Health Inc. (NDAQ:BLU) rallied 97.6 per cent in premarket trading on a major offer.

GSK Plc (NYSE:GSK) plans to buy the Canada-based drug developer in an all-cash deal for $2 billion.

Both companies announced the deal on Tuesday, which revolves round BELLUS’ experimental drug, camlipixant, which is in late-stage development for refractory chronic cough.

It is a condition can cause patients to cough more than 900 times a day. Roughly 10 million patients around the world live with it for more than a year. There are no approved therapies in the United States or Europe, so far.

GSK made an offer of U.S.$14.75 per share, which is more than double Bellus’ closing price of U.S.$7.26 on the NASDAQ on Monday.

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company extends its influence across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines.

BELLUS Health Inc. (TSX:BLU) is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, a P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.

On Wall Street, the company’s stock has performed admirably, having gained 72 per cent since this time last year, it has risen 75.6 per cent since the beginning of the year and is up 107.7 per cent in the last five days,

BELLUS Health Inc. (BLU) opened trading at C$9.71 per share.

More From The Market Online
Xcyte Digital Corp

Xcyte Digital Corp. acquires former Streamlined Communications assets

Xcyte Digital Corp. (TSXV:XCYT) has signed an agreement for sale of collateral with a Delaware limited liability company.
Hydrogen ESG concept

dynaCERT’s combustion engine enhancer is ramping up production

dynaCERT (TSX:DYA) eyes production of 1,000 units of its HydraGEN HG1, which improves fuel efficiency and emissions in combustion engines.
bull against a stock market graph background

Market Open: Carney for PM Ahead of BoC’s Interest Decision Tipping TSX Down |  Monday, March 10, 2025

Well Canada’s next Prime Minister has been elected, just ahead of the BoC’s next interest rate...
AI generated stock image

@ the Bell: TSX stumbles into the week

The TSX plunged over 300 points at the start of the week. Traders are avoiding risks due to ongoing concerns about the global trade…